Bristol Myers Squibb Reports Phase 3 extension Data for Efgartigimod in Chronic hand eczema

Bristol Myers Squibb today announced Phase 3 extension results for Efgartigimod in patients with Chronic hand eczema. The study demonstrated that Efgartigimod demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Chronic hand eczema and support the continued development of Efgartigimod in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Efgartigimod was consistent with previous observations, with no new safety signals identified.